Physician profile
Stephen C Ulrich
NPI 1881670792
$5,506.89
in general payments reported to CMS, 2019-2025
45 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $764 · 2021: $641 · 2022: $1,017 · 2023: $1,152 · 2024: $915 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547 · Education: $41.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.40 |
| Education | $41.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,287.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,173.70 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $474.40 | 2019-2022 | |
| Allergan, INC. | $180.15 | 2020-2021 | |
| Novo Nordisk INC | $175.42 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $165.51 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.43 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $145.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.46 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.45 | 2019-2024 | Jardiance |
| Pfizer INC. | $123.15 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $103.38 | 2019-2023 | Belsomra, Verquvo, Segluromet |
| Glaxosmithkline, LLC. | $102.06 | 2019-2023 | Trelegy Ellipta |
| Corcept Therapeutics | $89.04 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.37 | 2019-2023 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.